E6 TCR / Gilead - LARVOL DELTA

A phase I/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers. (ASCO 2017) - P2; "...Patients received a nonmyeloablative conditioning regimen of cyclophosphamide and fludarabine, a single infusion of E6 TCR T Cells, and systemic high-dose aldesleukin... E6 TCR T-cell therapy was safe at doses up to 2 x 1011 cells. Regression of metastatic HPV+ carcinoma occurred in two patients following treatment, suggesting that TCR T-cell therapy can mediate epithelial cancer regression."

Biomarker • Clinical • P1/2 data • Anal Carcinoma • Biosimilar • Immunology • Melanoma

Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions (clinicaltrials.gov) - P1; N=200; Recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Feb 2020 ➔ Feb 2021

Trial completion date • Biosimilar • Chronic Kidney Disease • Oncology

Kite Pharma: Corporate Presentaion (Kite Pharma) - Anticipated IND filing for solid tumors in H1 2016

Anticipated IND • Oncology

Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions (clinicaltrials.gov) - P1; N=1; Completed; Sponsor: National Cancer Institute (NCI); Recruiting ➔ Completed; N=200 ➔ 1; Trial completion date: Feb 2021 ➔ May 2019; Trial primary completion date: Feb 2020 ➔ May 2019

Enrollment change • Trial completion • Trial completion date • Trial primary completion date